Nakajima A, Kodama T, Morimoto S, Azuma M, Takeda K, Oshima H, Yoshino S, Yagita H, Okumura K
Department of Immunology, Juntendo University, School of Medicine, Tokyo, Japan.
J Immunol. 1998 Aug 15;161(4):1901-7.
The interaction between CD40 ligand (CD40L, CD154) and its receptor CD40 has been implicated in the establishment of cell-mediated immunity as well as humoral immune responses. To examine the role of CD40L in eliciting antitumor immunity, we introduced murine CD40L gene into P815 mastocytoma (CD40L-P815). CD40L-P815 cells underwent prompt rejection when inoculated s.c. into syngenic DBA/2 mice or athymic BALB/c nu/nu mice, which was mediated by NK cells and dependent on endogenous IL-12. The primary rejection of CD40L-P815 cells in DBA/2 mice elicited CD8+ T cell-mediated protective and systemic immunity against parental tumor cells, which was induced by CD4+ T cells and endogenous B7. These results indicated a potent antitumor effect of CD40L that is mediated by potentiation of host Ag-presenting cell functions, and introduction of CD40L will be useful as a new strategy of immuno-gene therapy against tumors.
CD40配体(CD40L,CD154)与其受体CD40之间的相互作用与细胞介导的免疫以及体液免疫反应的建立有关。为了研究CD40L在引发抗肿瘤免疫中的作用,我们将小鼠CD40L基因导入P815肥大细胞瘤(CD40L-P815)。当将CD40L-P815细胞皮下接种到同基因的DBA/2小鼠或无胸腺的BALB/c nu/nu小鼠中时,它们会迅速被排斥,这是由自然杀伤细胞介导的,并且依赖于内源性白细胞介素-12。DBA/2小鼠中CD40L-P815细胞的初次排斥引发了CD8+ T细胞介导的针对亲本肿瘤细胞的保护性和全身性免疫,这是由CD4+ T细胞和内源性B7诱导的。这些结果表明CD40L具有强大的抗肿瘤作用,其通过增强宿主抗原呈递细胞功能介导,并且引入CD40L将作为一种新的肿瘤免疫基因治疗策略。